BIIB BIOGEN INC.
Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 875045 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY2.3%
TTM net income YoY-78.4%
TTM EPS YoY-78.9%
Revenue 3-yr CAGR1.0%
Net income 3-yr CAGR-38.1%
Margins
Gross margin74.0%
Operating margin—
Net margin3.4%
FCF margin20.1%
EBITDA margin—
Returns
ROE1.9%
ROA1.1%
ROIC (approx.)—
Asset turnover0.34x
Leverage & solvency
Liabilities / assets41.0%
Debt / equity0.39x
Current ratio1.95x
Interest coverage—
Cash quality & payout
Operating cash flow / net income6.47x
Accruals ratio-6.2%
Payout ratio—
Capex / revenue1.7%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 | FY20232023-12-31 | FY20222022-12-31 | FY20212021-12-31 |
|---|---|---|---|---|---|
| Income statement | |||||
| Revenue | $9.89B | $9.68B | $9.84B | $10.17B | $10.98B |
| Cost of revenue | $2.40B | $2.31B | $2.53B | $2.28B | $2.11B |
| Gross profit | $7.49B | $7.37B | $7.30B | $7.90B | $8.87B |
| R&D expense | $1.78B | $1.98B | $2.45B | $2.23B | $2.50B |
| SG&A expense | $2.43B | $2.40B | $2.55B | $2.40B | $2.67B |
| Operating income | — | — | — | — | $2.84B |
| Interest expense | $267.50M | $250.30M | $246.90M | $246.60M | $253.60M |
| Pretax income | $1.56B | $1.91B | $1.30B | $3.59B | $1.75B |
| Income tax | $263.60M | $273.80M | $135.30M | $632.80M | $52.50M |
| Net income | $1.29B | $1.63B | $1.16B | $3.05B | $1.56B |
| EBITDA | — | — | — | — | $3.33B |
| EPS (basic) | 8.83 | 11.21 | 8.02 | 20.96 | 10.44 |
| EPS (diluted) | 8.79 | 11.18 | 7.97 | 20.87 | 10.40 |
| Weighted avg. shares (diluted) | 147.10M | 145.90M | 145.60M | 146.00M | 149.60M |
| Balance sheet | |||||
| Cash & equivalents | $3.01B | $2.38B | $1.05B | $3.42B | $2.26B |
| Short-term investments | $807.20M | $0 | $0 | $1.47B | $1.54B |
| Receivables | $1.34B | $1.40B | $1.66B | $1.71B | $1.55B |
| Inventory | $2.17B | $2.46B | $2.53B | $1.34B | $1.35B |
| Current assets | $8.97B | $7.46B | $6.86B | $9.79B | $7.86B |
| PP&E, net | $3.06B | $3.18B | $3.31B | $3.30B | $3.42B |
| Goodwill | $6.49B | $6.48B | $6.22B | $5.75B | $5.76B |
| Intangibles | $9.18B | $9.69B | $8.36B | $1.85B | $2.22B |
| Total assets | $29.44B | $28.05B | $26.84B | $24.55B | $23.88B |
| Current liabilities | $3.35B | $5.53B | $3.43B | $3.27B | $4.30B |
| Short-term debt | $0 | $1.75B | $150.00M | $0 | $999.10M |
| Long-term debt | $6.29B | $4.55B | $6.79B | $6.28B | $6.27B |
| Total debt | $6.29B | $6.30B | $6.94B | $6.28B | $7.27B |
| Total liabilities | $11.18B | $11.33B | $12.05B | $11.17B | $12.92B |
| Shareholders' equity | $18.26B | $16.72B | $14.80B | $13.40B | $10.90B |
| Net debt | $3.28B | $3.92B | $5.89B | $2.86B | $5.01B |
| Shares outstanding | 146.80M | 145.80M | 144.90M | 144.00M | 147.00M |
| Cash flow statement | |||||
| Operating cash flow | $2.20B | $2.88B | $1.55B | $1.38B | $3.64B |
| Capital expenditure | $153.80M | $153.70M | $277.00M | $240.30M | $258.10M |
| Free cash flow | $2.05B | $2.72B | $1.27B | $1.14B | $3.38B |
| Investing cash flow | -$1.37B | -$799.20M | -$4.10B | $1.58B | -$563.70M |
| Financing cash flow | -$301.90M | -$683.50M | $149.30M | -$1.75B | -$2.09B |
| Depreciation & amortization | $779.90M | $673.20M | $494.80M | $518.40M | $487.70M |
| Stock-based compensation | $290.80M | $291.20M | $264.20M | $254.10M | $238.60M |
| Share buybacks | — | $0 | $0 | $750.00M | $1.80B |
Free plan shows the latest 5 periods; Pro shows all 19 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.